查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球抗体发现人工智慧市场：按技术、解决方案、应用、最终用户和国家分類的分析和预测（2025-2035 年）
市场调查报告书
商品编码
1885395

全球抗体发现人工智慧市场：按技术、解决方案、应用、最终用户和国家分類的分析和预测（2025-2035 年）

AI in Antibody Discovery Market - A Global and Regional Analysis: Focus on Technology, Solution, Application, End User, and Country - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 132 Pages | 商品交期: 1-5个工作天内

价格

全球抗体发现人工智慧市场规模预计将从 2024 年的约 4.104 亿美元成长到 2035 年的约 48.431 亿美元，复合年增长率约为 24.76%。

儘管传统抗体药物研发方法存在诸多局限性，例如高成本、研发週期长、失败率高等，但人工智慧技术，例如深度学习、生成式人工智慧和抗体特异性大规模语言模型（LLM），正在革新靶点识别、先导化合物发现和优化流程，显着缩短研发週期并提高成功率。

关键市场统计数据
预测期 2025-2035
2025 年评估 5.299亿美元
2035 年预测 48.431亿美元
复合年增长率 24.76%

全球抗体发现人工智慧市场由人工智慧技术提供者、製药和生物技术公司、受託研究机构(CRO) 以及学术和研究机构组成。各机构正日益利用自主药物发现平台，以最小的人工干预实现迭代式设计-测试-优化循环。生成式人工智慧和多组体学整合正在加速个人化抗体疗法的开发，而云端基础方案、咨询服务和本地部署的人工智慧工具则扩大了其可及性。人工智慧Start-Ups与成熟製药公司之间的策略合作和融资正在加速平台规模化、临床检验和商业化。这些因素共同推动了快速创新，提高了营运效率，并为市场的持续成长奠定了基础。

基于技术层面，结构预测领域预计将成为市场的主要驱动力，因为它在精确模拟抗体折迭、三维结构和稳定性方面发挥关键作用。精准的结构预测能够帮助製药和生技公司缩短实验週期、提高结合亲和性并加速有效抗体的发现。其他技术，例如表位定位和从头设计，透过优化候选抗体筛选和提高潜在治疗效果，对结构预测有补充作用。

从解决方案来看，人工智慧软体平台预计将引领市场，因为它提供了一个全面的抗体发现框架，整合了预测建模、生成式人工智慧和湿实验室相容性。其扩充性、多功能性和加速研究工作流程的能力使其成为全球製药和生物技术公司的首选。云端基础和本地部署工具以及咨询服务支援其在各种研究环境中的应用。

从应用领域来看，标靶辨识预计将成为市场成长的主要驱动力，因为它为选择具有治疗意义的抗原奠定了基础。人工智慧驱动的标靶预测能够提高准确性，缩短发现时间，并提升下游抗体开发的效率。先导化合物的发现和优化能够进一步优化候选药物，进而提高其疗效、稳定性和免疫抗原性。

从终端用户来看，製药、生物技术和平台开发产业预计将成为市场的主要驱动力，因为这些产业高度采用人工智慧平台来加速研发、优化产品线并将新型抗体推向市场。合约研究机构（CRO）和学术机构也做出了重要贡献，尤其是在早期药物发现和检验。

从区域来看，北美凭藉其完善的医疗基础设施、大量的研发投入、强有力的监管支持以及对抗体发现人工智慧平台的早期应用，在市场中占据领先地位。欧洲市场较为成熟，拥有强大的合作网络和临床应用。亚太地区正经历快速成长，这得益于生物技术领域研发投入的增加、人工智慧新创企业的崛起以及医疗服务可近性的提升。包括拉丁美洲、中东和非洲在内的世界其他地区，由于对医疗保健和生物技术领域的投资不断增加，也蕴藏着巨大的成长潜力。

本报告调查了全球抗体发现人工智慧市场，并总结了关键趋势、市场影响因素分析、法律制度、研发管线分析、市场规模趋势和预测、按各个细分市场、地区/主要国家进行的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

范围和定义

第一章 市场：产业展望

  • 市场概览
    • 对下一代生物製药的需求快速成长
    • 利用人工智慧在抗体发现领域实现个人化精准医疗
  • 市场趋势
    • 采用抗体特异性大规模语言模型（LLM）
    • 策略联盟和增加投资
  • 监管状态/合规性
    • 美国
    • EU
    • 亚太地区
    • 其他地区
  • 定价分析
  • 实施策略
    • 人工智慧驱动的生物标记和伴随诊断整合
    • 利用策略伙伴关係
  • 市场动态
    • 驱动因素、挑战和机会：评估当前和未来的影响
    • 市场驱动因素
    • 市场挑战
    • 市场机会

第二章 技术

  • 技术摘要
  • 结构预测
  • 表位/互补位预测
  • 从头抗体设计
  • 亲和性成熟与优化
  • 其他的

第三章答案

  • 解决方案摘要
  • 人工智慧软体平台
  • 云端基础的解决方案
  • 本地部署人工智慧工具
  • 咨询和整合服务

第四章 应用

  • 使用摘要
  • 目标识别
  • 先导抗体发现
  • 先导药物最适化
  • 其他的

第五章 最终用户

  • 最终用户摘要
  • 製药、生物技术和平台开发公司
  • 合约研究组织（CRO）
  • 学术研究机构
  • 其他的

第六章 区域

  • 区域摘要
  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他地区
    • 区域概览
    • 市场成长驱动因素
    • 市场问题
    • 市场规模及预测
    • 按国家/地区

第七章 市场：竞争基准化分析与公司概况

  • 关键策略和发展（按公司划分）
  • 公司简介
    • LabGenius Therapeutics
    • BigHat Biosciences, Inc.
    • Generate Biomedicines, Inc.
    • InveniAI LLC
    • Antiverse
    • EVQLV Inc.
    • Chai Discovery Inc.
    • MAbSilico
    • Cradle Bio BV
    • Alloy Therapeutics, Inc.

第八章调查方法

Product Code: BHL3201SA

This report can be delivered within 1 working day.

Global AI in antibody discovery market: Industry Overview

The global AI in antibody discovery market was valued at approximately $410.4 million in 2024 and is projected to grow $4,843.1 million by 2035, at a CAGR of around 24.76%. Growth is driven by the limitations of conventional antibody discovery methods, which are costly, time-intensive, and prone to high failure rates. AI-enabled technologies, including deep learning, generative AI, and antibody-specific large language models (LLMs), are transforming the process of target identification, lead discovery, and optimization, significantly reducing development timelines and improving success rates.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$529.9 Million
2035 Forecast$4,843.1 Million
CAGR24.76%

The global AI in antibody discovery market encompasses AI technology providers, pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic and research institutions. Organizations are increasingly leveraging autonomous discovery platforms to enable iterative design-test-optimize cycles with minimal human intervention. Generative AI and multi-omics integration are facilitating personalized antibody therapeutics, while cloud-based solutions, consulting services, and on-premise AI tools expand accessibility. Strategic collaborations and funding between AI startups and established pharmaceutical companies accelerate platform scale-up, clinical validation, and commercialization. Collectively, these factors are driving rapid innovation, improving operational efficiency, and positioning the market for sustained growth.

Global AI in Antibody Discovery Market Lifecycle Stage

The global AI in antibody discovery market is in the expansion phase, characterized by rapid adoption, substantial investment, and strategic collaborations between innovative startups and established pharmaceutical companies. High attrition rates and the escalating costs associated with traditional antibody discovery have catalysed the transition toward AI-enabled platforms. Integration of AI with wet lab experimentation enhances efficiency, reduces failure rates, and supports iterative optimization cycles. The use of antibody-specific LLMs improves predictive accuracy for structure, binding affinity, and immunogenicity, increasing the probability of successful antibody candidates.

Despite these supporting factors, several challenges remain, including data bottlenecks from limited high-quality datasets and validation gaps requiring experimental confirmation. However, the market presents substantial growth opportunities through generative AI, autonomous discovery platforms, and multi-omics integration, enabling the design of novel antibodies and personalized therapeutics. Expansion into emerging regions with increasing healthcare investments, supportive regulatory frameworks, and growing R&D initiatives further positions the market for sustained growth. Stakeholders are increasingly focusing on technological advancement, strategic alliances, and scalable solutions to optimize antibody discovery efficiency and maintain a competitive advantage.

Market Segmentation:

Segmentation 1: By Technology

  • Structure Prediction
  • Epitope/Paratope Prediction
  • De Novo Antibody Design
  • Affinity Maturation & Optimization
  • Others

Structure Prediction is expected to lead the market due to its critical role in accurately modelling antibody folding, 3D structures, and stability. By enabling precise structural predictions, pharmaceutical and biotechnology companies can reduce experimental cycles, improve binding affinity, and accelerate the discovery of effective antibodies. Other technologies, such as epitope mapping and de novo design, complement structure prediction by refining candidate selection and optimizing therapeutic potential.

Segmentation 2: By Solution

  • AI Software Platforms
  • Cloud-Based Solutions
  • On-Premise AI Tools
  • Consulting & Integration Services

AI Software Platforms are projected to lead the market as they provide comprehensive frameworks for antibody discovery, integrating predictive modelling, generative AI, and wet lab compatibility. Their scalability, versatility, and ability to accelerate research workflows make them the preferred choice for pharmaceutical and biotechnology companies globally. Cloud-based and on-premise tools, along with consulting services, support adoption across diverse research settings.

Segmentation 3: By Application

  • Target Identification
  • Lead Antibody Discovery
  • Lead Optimization
  • Others

Target Identification is expected to lead the application segment because it is fundamental for selecting therapeutically relevant antigens. AI-driven target prediction improves precision, reduces discovery timelines, and enhances downstream antibody development efficiency. Lead discovery and optimization further refine candidates to improve efficacy, stability, and immunogenicity.

Segmentation 4: By End User

  • Pharmaceutical, Biotechnology, and Platform Developing Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Others

Pharmaceutical, biotechnology, and platform developing companies are expected to lead the market due to their high adoption of AI-enabled platforms to accelerate R&D, optimize pipelines, and bring novel antibodies to market. CROs and academic institutes also contribute significantly, particularly in early-stage discovery and validation.

Segmentation 5: By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest-of-the-World

North America leads the market with a well-established healthcare infrastructure, significant R&D investment, strong regulatory support, and early adoption of AI platforms in antibody discovery. Europe represents a mature market with robust collaborations and clinical adoption. The Asia-Pacific region is witnessing rapid growth driven by increasing biotech R&D, emerging AI companies, and improving healthcare access. Rest-of-the-world regions, including Latin America, the Middle East, and Africa, offer additional growth opportunities due to rising investments in healthcare and biotechnology.

Demand - Drivers and Limitations

Demand drivers for the global AI in antibody discovery market:

  • High attrition rates and costs associated with traditional antibody discovery methods
  • AI integration with wet labs accelerating antibody discovery

Limitations for the global AI in antibody discovery market:

  • Data bottlenecks hindering innovation in AI-enabled antibody discovery
  • Validation gap in AI-driven antibody discovery

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in global AI in antibody discovery market, including generative AI, autonomous platforms, and antibody-specific LLMs. It guides R&D investment decisions, pipeline optimization, and technology adoption, helping companies prioritize initiatives that accelerate lead identification and antibody optimization. The report provides actionable insights on platform scalability, wet lab integration, and predictive modelling accuracy, allowing stakeholders to reduce development costs, improve success rates, and maintain a competitive advantage in the rapidly evolving antibody discovery market.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across technology, solution, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the AI-driven antibody discovery ecosystem.

Key Market Players and Competitive Landscape

The global AI in antibody discovery market is characterized by a highly competitive and evolving landscape, with participation from innovative biotechnology startups, established pharmaceutical companies, and AI technology providers. Key players include:

  • LabGenius Therapeutics
  • BigHat Biosciences, Inc.
  • Generate: Biomedicines, Inc.
  • Alloy Therapeutics, Inc.
  • InveniAI LLC
  • Antiverse Ltd.
  • EVQLV, Inc.
  • Chai Discovery, Inc.
  • Cradle Bio B.V.
  • MAbsillco

Competitive benchmarking highlights mergers and acquisitions, funding activities, licensing deals, and collaborations with pharmaceutical organizations, reflecting the growing emphasis on innovation and speed-to-market. Companies are evaluated based on market presence, technological capabilities, strategic initiatives, and product portfolios. Detailed company profiles cover target end users, technological focus areas, and expert analyst perspectives, providing stakeholders with actionable insights into investment opportunities, market positioning, and strategic growth pathways. This intelligence enables organizations to effectively align their R&D and commercialization strategies with emerging market dynamics of the global AI in antibody discovery market.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

  • 1.1 Market Overview
    • 1.1.1 Surging Demand for Next-Generation Biologics
    • 1.1.2 Leveraging AI for Personalized Precision Medicine in Antibody Discovery
  • 1.2 Market Trends
    • 1.2.1 Adoption of Antibody-Specific Large Language Models (LLMs)
    • 1.2.2 Increasing Strategic Collaborations and Investments
  • 1.3 Regulatory Landscape / Compliance
    • 1.3.1 U.S.
    • 1.3.2 E.U.
      • 1.3.2.1 France
      • 1.3.2.2 Italy
    • 1.3.3 Asia-Pacific
      • 1.3.3.1 China
      • 1.3.3.2 Japan
    • 1.3.4 Rest-of-the-World
      • 1.3.4.1 Brazil
      • 1.3.4.2 U.A.E.
  • 1.4 Pricing Analysis
  • 1.5 Implementation Strategies
    • 1.5.1 AI-Driven Biomarker and Companion Diagnostic Integration
    • 1.5.2 Leveraging Strategic Partnerships
  • 1.6 Market Dynamics
    • 1.6.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
    • 1.6.2 Market Drivers
      • 1.6.2.1 High Attrition Rates and Costs Associated with Traditional Antibody Discovery Methods
      • 1.6.2.2 AI Integration with Wet Labs Accelerating Antibody Discovery
    • 1.6.3 Market Challenges
      • 1.6.3.1 Data Bottlenecks Hindering Innovation in AI-Enabled Antibody Discovery
      • 1.6.3.2 Validation Gap in AI-Driven Antibody Discovery
    • 1.6.4 Market Opportunities
      • 1.6.4.1 Generative AI and Deep Learning for Novel Antibody Design
      • 1.6.4.2 Autonomous Discovery Platforms and AI Agents
      • 1.6.4.3 Establishing Antibody Data Foundries and Collaborative Networks

2 Technology

  • 2.1 Technology Summary
  • 2.2 Structure Prediction
  • 2.3 Epitope/Paratope Prediction
  • 2.4 De Novo Antibody Design
  • 2.5 Affinity Maturation and Optimization
  • 2.6 Others

3 Solution

  • 3.1 Solution Summary
  • 3.2 AI Software Platforms
  • 3.3 Cloud-Based Solutions
  • 3.4 On-Premise AI Tools
  • 3.5 Consulting and Integration Services

4 Application

  • 4.1 Application Summary
  • 4.2 Target Identification
  • 4.3 Lead Antibody Discovery
  • 4.4 Lead Optimization
  • 4.5 Others

5 End User

  • 5.1 End User Summary
  • 5.2 Pharmaceutical, Biotechnology, and Platform Developing Companies
  • 5.3 Contract Research Organizations (CROs)
  • 5.4 Academic and Research Institutes
  • 5.5 Others

6 Region

  • 6.1 Regional Summary
  • 6.2 North America
    • 6.2.1 Regional Overview
    • 6.2.2 Driving Factors for Market Growth
    • 6.2.3 Factors Challenging the Market
    • 6.2.4 Market Sizing and Forecast
    • 6.2.5 By Country
      • 6.2.5.1 U.S.
    • 6.2.6 Market Sizing and Forecast
      • 6.2.6.1 Canada
    • 6.2.7 Market Sizing and Forecast
  • 6.3 Europe
    • 6.3.1 Regional Overview
    • 6.3.2 Driving Factors for Market Growth
    • 6.3.3 Factors Challenging the Market
    • 6.3.4 Market Sizing and Forecast
    • 6.3.5 By Country
      • 6.3.5.1 U.K.
    • 6.3.6 Market Sizing and Forecast
      • 6.3.6.1 Germany
    • 6.3.7 Market Sizing and Forecast
      • 6.3.7.1 France
    • 6.3.8 Market Sizing and Forecast
      • 6.3.8.1 Italy
    • 6.3.9 Market Sizing and Forecast
      • 6.3.9.1 Spain
    • 6.3.10 Market Sizing and Forecast
      • 6.3.10.1 Rest-of-Europe
    • 6.3.11 Market Sizing and Forecast
  • 6.4 Asia-Pacific
    • 6.4.1 Regional Overview
    • 6.4.2 Driving Factors for Market Growth
    • 6.4.3 Factors Challenging the Market
    • 6.4.4 Market Sizing and Forecast
    • 6.4.5 By Country
      • 6.4.5.1 Japan
    • 6.4.6 Market Sizing and Forecast
      • 6.4.6.1 China
    • 6.4.7 Market Sizing and Forecast
      • 6.4.7.1 India
    • 6.4.8 Market Sizing and Forecast
      • 6.4.8.1 Australia
    • 6.4.9 Market Sizing and Forecast
      • 6.4.9.1 South Korea
    • 6.4.10 Market Sizing and Forecast
      • 6.4.10.1 Rest-of-the-Asia-Pacific
    • 6.4.11 Market Sizing and Forecast
  • 6.5 Rest-of-the-World
    • 6.5.1 Market Sizing and Forecast

7 Markets - Competitive Benchmarking & Company Profiles

  • 7.1 Key Strategies and Developments (by Company)
    • 7.1.1 Funding Activities
    • 7.1.2 Mergers and Acquisitions
    • 7.1.3 Product Launches
    • 7.1.4 Partnerships, Collaborations, and Business Expansions
  • 7.2 Company Profiles
    • 7.2.1 LabGenius Therapeutics
      • 7.2.1.1 Overview
      • 7.2.1.2 Top Products/Product Portfolio
      • 7.2.1.3 Top Competitors
      • 7.2.1.4 Target Customers
      • 7.2.1.5 Key Personal
      • 7.2.1.6 Analyst View
    • 7.2.2 BigHat Biosciences, Inc.
      • 7.2.2.1 Overview
      • 7.2.2.2 Top Products/Product Portfolio
      • 7.2.2.3 Top Competitors
      • 7.2.2.4 Target Customers
      • 7.2.2.5 Key Personal
      • 7.2.2.6 Analyst View
    • 7.2.3 Generate Biomedicines, Inc.
      • 7.2.3.1 Overview
      • 7.2.3.2 Top Products/Product Portfolio
      • 7.2.3.3 Top Competitors
      • 7.2.3.4 Target Customers
      • 7.2.3.5 Key Personal
      • 7.2.3.6 Analyst View
    • 7.2.4 InveniAI LLC
      • 7.2.4.1 Overview
      • 7.2.4.2 Top Products/Product Portfolio
      • 7.2.4.3 Top Competitors
      • 7.2.4.4 Target Customers
      • 7.2.4.5 Key Personal
      • 7.2.4.6 Analyst View
    • 7.2.5 Antiverse
      • 7.2.5.1 Overview
      • 7.2.5.2 Top Products/Product Portfolio
      • 7.2.5.3 Top Competitors
      • 7.2.5.4 Target Customers
      • 7.2.5.5 Key Personal
      • 7.2.5.6 Analyst View
    • 7.2.6 EVQLV Inc.
      • 7.2.6.1 Overview
      • 7.2.6.2 Top Products/Product Portfolio
      • 7.2.6.3 Top Competitors
      • 7.2.6.4 Target Customers
      • 7.2.6.5 Key Personal
      • 7.2.6.6 Analyst View
    • 7.2.7 Chai Discovery Inc.
      • 7.2.7.1 Overview
      • 7.2.7.2 Top Products/Product Portfolio
      • 7.2.7.3 Top Competitors
      • 7.2.7.4 Target Customers
      • 7.2.7.5 Key Personal
      • 7.2.7.6 Analyst View
    • 7.2.8 MAbSilico
      • 7.2.8.1 Overview
      • 7.2.8.2 Top Products/Product Portfolio
      • 7.2.8.3 Top Competitors
      • 7.2.8.4 Target Customers
      • 7.2.8.5 Key Personal
      • 7.2.8.6 Analyst View
    • 7.2.9 Cradle Bio B.V.
      • 7.2.9.1 Overview
      • 7.2.9.2 Top Products/Product Portfolio
      • 7.2.9.3 Top Competitors
      • 7.2.9.4 Target Customers
      • 7.2.9.5 Key Personal
      • 7.2.9.6 Analyst View
    • 7.2.10 Alloy Therapeutics, Inc.
      • 7.2.10.1 Overview
      • 7.2.10.2 Top Products/Product Portfolio
      • 7.2.10.3 Top Competitors
      • 7.2.10.4 Target Customers
      • 7.2.10.5 Key Personal
      • 7.2.10.6 Analyst View

8 Research Methodology

  • 8.1 Data Sources
    • 8.1.1 Primary Data Sources
    • 8.1.2 Secondary Data Sources
    • 8.1.3 Data Triangulation
  • 8.2 Market Estimation and Forecast

List of Figures

  • Figure 1: AI in Antibody Discovery Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure 2: Global Market Snapshot, 2024
  • Figure 3: AI in Antibody Discovery Market, $Million, 2024 and 2035
  • Figure 4: AI in Antibody Discovery Market (by Technology), $Million, 2024, 2030, and 2035
  • Figure 5: AI in Antibody Discovery Market (by Solution), $Million, 2024, 2030, and 2035
  • Figure 6: AI in Antibody Discovery Market (by Application), $Million, 2024, 2030, and 2035
  • Figure 7: AI in Antibody Discovery Market (by End User), $Million, 2024, 2030, and 2035
  • Figure 8: AI application across the Antibody Discovery Workflow
  • Figure 9: Advanced Antibody Design and Optimization
  • Figure 10: AI in Antibody Discovery Market (Structure Prediction), $Million, 2024-2035
  • Figure 11: AI in Antibody Discovery Market (Epitope/Paratope Prediction), $Million, 2024-2035
  • Figure 12: AI in Antibody Discovery Market (De Novo Antibody Design), $Million, 2024-2035
  • Figure 13: AI in Antibody Discovery Market (Affinity Maturation and Optimization), $Million, 2024-2035
  • Figure 14: AI in Antibody Discovery Market (Others), $Million, 2024-2035
  • Figure 15: AI in Antibody Discovery Market (AI Software Platforms), $Million, 2024-2035
  • Figure 16: AI in Antibody Discovery Market (Cloud-Based Solutions), $Million, 2024-2035
  • Figure 17: AI in Antibody Discovery Market (On-Premise AI Tools), $Million, 2024-2035
  • Figure 18: AI in Antibody Discovery Market (Consulting and Integration Services), $Million, 2024-2035
  • Figure 19: AI in Antibody Discovery Market (Target Identification), $Million, 2024-2035
  • Figure 20: AI in Antibody Discovery Market (Lead Antibody Discovery), $Million, 2024-2035
  • Figure 21: AI in Antibody Discovery Market (Lead Optimization), $Million, 2024-2035
  • Figure 22: AI in Antibody Discovery Market (Others), $Million, 2024-2035
  • Figure 23: AI in Antibody Discovery Market (Pharmaceutical, Biotechnology, and Platform Developing Companies), $Million, 2024-2035
  • Figure 24: AI in Antibody Discovery Market (Contract Research Organizations (CROs), $Million, 2024-2035
  • Figure 25: AI in Antibody Discovery Market (Academic and Research Institutes), $Million, 2024-2035
  • Figure 26: AI in Antibody Discovery Market (Others), $Million, 2024-2035
  • Figure 27: North America AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 28: U.S. AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 29: Canada AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 30: Europe AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 31: U.K. AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 32: Germany AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 33: France AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 34: Italy AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 35: Spain AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 36: Rest-of-Europe AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 37: Asia-Pacific AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 38: Japan AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 39: China AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 40: India AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 41: Australia AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 42: South Korea AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 43: Rest-of-Asia-Pacific AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 44: Rest-of-the-World AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 45: Data Triangulation
  • Figure 46: Top-Down and Bottom-Up Approach
  • Figure 47: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Competitive Landscape Analysis
  • Table 3: Companies Involved in Funding and Collaboration
  • Table 4: Leading Platforms and their Pricing Model
  • Table 5: AI in Antibody Discovery Market (by Region), $Million, 2024-2035